Monday, February 10, 2025

Semaglutide 7.2 mg Drives Significant Weight Reduction in Novo Nordisk Trial

Similar articles

Novo Nordisk has unveiled impressive outcomes from its latest STEP UP obesity trial, showcasing the efficacy of semaglutide 7.2 mg in achieving substantial weight loss among participants. This phase 3b study involved over 1,400 adults battling obesity, highlighting Novo Nordisk’s commitment to advancing obesity treatment solutions.

Outstanding Weight Loss Results

Subscribe Weekly Market Access News

* indicates required

The STEP UP trial, spanning 72 weeks, meticulously compared the effects of semaglutide 7.2 mg against a lower dose of 2.4 mg and a placebo, all administered weekly alongside lifestyle interventions. The primary objective—to demonstrate superior weight loss with the higher dose—was successfully met, with participants experiencing an average weight reduction of 20.7% compared to 17.5% with the 2.4 mg dose and a mere 2.4% in the placebo group. Notably, over a third of those on the 7.2 mg regimen achieved a weight loss exceeding 25%, underscoring the drug’s potent impact.

Safety and Tolerability Profile

Safety assessments revealed that semaglutide 7.2 mg maintained a favorable tolerability profile, with gastrointestinal issues being the most common adverse effects. Importantly, these side effects were mostly mild to moderate and tended to lessen over time, aligning with expectations for GLP-1 receptor agonists. This balance between efficacy and safety makes semaglutide 7.2 mg a promising option for individuals seeking significant weight loss through medical intervention.

  • Semaglutide 7.2 mg achieved an average weight loss of 20.7%, significantly outperforming both the lower dose and placebo.
  • 33.2% of participants on the higher dose reached or surpassed a 25% weight loss threshold.
  • Adverse effects remained manageable, primarily involving transient gastrointestinal discomfort.
  • Results bolster Novo Nordisk’s portfolio, positioning semaglutide as a leading treatment in obesity management.

Novo Nordisk’s STEP UP trial marks a pivotal advancement in obesity treatment, offering robust evidence for semaglutide 7.2 mg’s effectiveness and safety. These findings not only enhance the clinical profile of semaglutide but also provide valuable insights for healthcare providers and patients in managing obesity. As the company prepares to present detailed results at upcoming scientific conferences, the medical community eagerly anticipates further validation of semaglutide’s role in combating obesity and its associated health risks.

Source


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article